News & Updates
Filter by Specialty:

MSP Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
03 Oct 2024
byJairia Dela Cruz
The use of abatacept in adults at high risk of rheumatoid arthritis helps protect against disease onset, as shown in the phase IIB APIPPRA study.
MSP Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
03 Oct 2024![[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC](https://sitmspst.blob.core.windows.net/images/articles/amivantamab-plus-chemo-tied-to-better-outcomes-vs-chemo-alone-in-advanced-nsclc-e2167ed1-51a8-44c8-93d2-9f1c03576b98-square.jpg)
[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC
17 Sep 2024
byStephen Padilla
Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.